| ADORA1 |
ADORA1: Adenosine receptor A1 |
GPR101 |
GPR101: Probable G-protein coupled receptor 101 |
2.43 |
Evidence |
|
| ADORA1 |
ADORA1: Adenosine receptor A1 |
XCR1 |
XCR1, CCXCR1, GPR5: Chemokine XC receptor 1 |
2.43 |
Evidence |
|
| CDC25B |
CDC25B, CDC25HU2: M-phase inducer phosphatase 2 |
LYN |
LYN: Tyrosine-protein kinase Lyn |
2.43 |
Evidence |
|
| CDC25A |
CDC25A: M-phase inducer phosphatase 1 |
CCNF |
CCNF: G2/mitotic-specific cyclin-F |
2.43 |
Evidence |
|
| TYK2 |
TYK2: Non-receptor tyrosine-protein kinase TYK2 |
CAPN12 |
CAPN12: Calpain-12 |
2.43 |
Evidence |
|
| PML |
PML, MYL, RNF71, TRIM19: Probable transcription factor PML |
ZBTB16 |
ZBTB16, PLZF, ZNF145: Zinc finger and BTB domain-containing protein 16 |
2.43 |
Evidence |
|
| PTPN6 |
PTPN6, HCP, PTP1C: Tyrosine-protein phosphatase non-receptor type 6 |
SHB |
SHB: SH2 domain-containing adapter protein B |
2.43 |
Evidence |
|
| ADORA2B |
ADORA2B: Adenosine receptor A2b |
OR8B8 |
OR8B8: Olfactory receptor 8B8 |
2.43 |
Evidence |
|
| ADORA2A |
ADORA2A, ADORA2: Adenosine receptor A2a |
GPR146 |
GPR146, PGR8: Probable G-protein coupled receptor 146 |
2.43 |
Evidence |
|
| CD1C |
CD1C: T-cell surface glycoprotein CD1c precursor |
EMB |
EMB: Embigin precursor |
2.43 |
Evidence |
|
| CD1C |
CD1C: T-cell surface glycoprotein CD1c precursor |
SERPINH1 |
SERPINH1, CBP1, PIG14, CBP2, HSP47, SERPINH2: Serpin H1 precursor |
2.43 |
Evidence |
|
| RXRB |
RXRB, NR2B2: Retinoic acid receptor RXR-beta |
TCF19 |
TCF19, SC1: Transcription factor 19 |
2.43 |
Evidence |
|
| RXRB |
RXRB, NR2B2: Retinoic acid receptor RXR-beta |
TRIM41 |
TRIM41: Tripartite motif-containing protein 41 |
2.43 |
Evidence |
|
| RXRB |
RXRB, NR2B2: Retinoic acid receptor RXR-beta |
PHF6 |
PHF6, KIAA1823: PHD finger protein 6 |
2.43 |
Evidence |
|
| RXRB |
RXRB, NR2B2: Retinoic acid receptor RXR-beta |
TRIM50B |
TRIM73, TRIM50B: Tripartite motif-containing protein 73 |
2.43 |
Evidence |
|
| HTR1E |
HTR1E: 5-hydroxytryptamine receptor 1E |
CCR2 |
CCR2, CMKBR2: C-C chemokine receptor type 2 |
2.43 |
Evidence |
|
| HTR2C |
HTR2C, HTR1C: 5-hydroxytryptamine receptor 2C |
GPR62 |
GPR62: Probable G-protein coupled receptor 62 |
2.43 |
Evidence |
|
| HTR2C |
HTR2C, HTR1C: 5-hydroxytryptamine receptor 2C |
C9orf47 |
EDG3: Sphingosine 1-phosphate receptor Edg-3 |
2.43 |
Evidence |
|
| HTR2C |
HTR2C, HTR1C: 5-hydroxytryptamine receptor 2C |
HTR4 |
HTR4: 5-hydroxytryptamine receptor 4 |
2.43 |
Evidence |
|
| HTR2A |
HTR2A, HTR2: 5-hydroxytryptamine receptor 2A |
GPR62 |
GPR62: Probable G-protein coupled receptor 62 |
2.43 |
Evidence |
|
| HTR2A |
HTR2A, HTR2: 5-hydroxytryptamine receptor 2A |
HTR4 |
HTR4: 5-hydroxytryptamine receptor 4 |
2.43 |
Evidence |
|
| TNFRSF7 |
CD27, TNFRSF7: CD27 antigen precursor |
EDAR |
EDAR, DL: Tumor necrosis factor receptor superfamily member EDAR precursor |
2.43 |
Evidence |
|
| TNFRSF7 |
CD27, TNFRSF7: CD27 antigen precursor |
TNFRSF25 |
TNFRSF25, APO3, UNQ455/PRO779, DDR3, DR3, TNFRSF12, WSL, WSL1: Tumor necrosis fa |
2.43 |
Evidence |
|
| MSN |
MSN: Moesin |
NOXA1 |
NOXA1, RP13-927H1.1-001: NADPH oxidase activator 1 |
2.43 |
Evidence |
|
| CD40 |
CD40, TNFRSF5: Tumor necrosis factor receptor superfamily member 5 precursor |
EDAR |
EDAR, DL: Tumor necrosis factor receptor superfamily member EDAR precursor |
2.43 |
Evidence |
|